DexCom (DXCM) concentration risks

The company's disclosed concentration profile is defined by two large-share exposures that together create a compounding dependency on a single product and a narrow supplier base. The filing states that sales of CGM systems will account for substantially all of product revenue for the foreseeable future, a large-share mixed exposure. The mixed character reflects the dual nature of this dependency: structurally, the company's entire commercial platform is built around continuous glucose monitoring, and the mission-critical nature of the device creates durable demand; but idiosyncratically, the single-product reliance means any clinical safety event, reimbursement change, or competitive displacement could affect substantially all revenues at once. Compounding this is a supply-chain dependency on single- or sole-source suppliers for certain key materials and components, also a large-share exposure by disclosed size with a dependency character. For a medical device manufacturer, supply chain disruptions in sole-source components can directly impair the ability to manufacture the one product that generates the revenue base. A quality event, capacity constraint, or supplier financial stress at a key sole-source vendor would therefore have an immediate impact on product availability. Together, the two exposures reinforce one another's materiality: concentrated revenue in a single product amplifies the consequence of any supply disruption affecting that product's manufacturing. On balance, monitoring supplier diversification progress and CGM competitive dynamics — including reimbursement policy for continuous glucose monitoring — are the primary watchpoints for the investment case.

For the engine’s reasoning on DXCM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.